Valinor, an AI biotech developing multiomics‑trained machine‑learning models to improve clinical trial design and patient responder identification, closed a $13 million seed round led by CRV, Harpoon Ventures and others. The San Francisco startup plans to expand proprietary datasets and hire ML and multiomics talent to accelerate its platform. Valinor says its models link matched multiomics profiles with clinical outcomes to surface molecular features underlying patient responses; founder Joshua Pacini positioned the platform as a tool to reduce R&D costs and boost trial success rates. The company will pursue collaborations with pharma partners to pilot model‑driven cohort selection and adaptive trial designs. Short‑term validation milestones will include retrospective case studies and prospective consortium projects; regulatory acceptance of model‑informed trial design remains nascent but is a growing area of industry‑regulator dialogue.